Chronic lymphocytic leukemia (CLL) is an indolent B-cell nonHodgkin's lymphoma that may transform into higher-grade lymphoma. The transformation involves an increased number of prolymphocytic cells, termed prolymphocytic transformation (PLT) or the development of diffuse large B-cell lymphoma (DLBL), also referred to as Richter's transformation (RT). To analyze whether activation-induced cytidine deaminase (AID), which is essential for somatic hypermutation (SHM) of normal B-cells, and malfunction of SHM termed aberrant somatic hypermutation (ASHM) are associated with higher-grade transformation of CLL, AID mRNA expression and the mutation pattern of c-MYC, PAX-5 and RhoH genes were analyzed in eight cases of CLL without transformation and in 21 cases that showed RT or PLT. Chronic lymphocytic leukemia cases, which showed no transformation or eventually transformed into higher-grade lymphoma, showed low levels of AID mRNA expression and low frequency of mutations of c-MYC, PAX-5 and RhoH genes. In both RT and PLT, high-levels of AID mRNA expression and high-frequency mutations of c-MYC, PAX-5 and RhoH genes were detected. These results indicate that AID expression and ASHM are associated with higher-grade transformation of CLL and provide further evidences that AID expression and ASHM may be activated during the clonal history of B-cell lymphomas.
Introduction
Transformation of chronic lymphocytic leukemia (CLL) to a more aggressive lymphoma occurs in about 5-10% of patients, and is generally associated with acceleration of the disease and poor clinical prognosis. 1, 2 The histological alterations of transformed CLLs may involve an increased number of prolymphocytic cells, termed prolymphocytic transformation (PLT) or the emergence of diffuse large B-cell lymphoma (DLBL), also referred to as Richter's syndrome or transformation (RT). 3 The molecular mechanisms involved in these transformations are only partially explored and not fully understood. Previous studies documented different genetic defects in transformed CLLs, including trisomy 12, deletions and translocations in chromosomes 11, 13 and 14, mutations of p53, p16INK4A and p21 genes and microsatellite instability (reviewed by Tsimberidou and Keating 4 ). Although these genetic defects occur more frequently in CLL patients with transformation than in patients without transformation, each of these individual genetic alterations is observed in only a subset of patients; therefore, none of them seems to be sufficient to trigger the transformation alone. The heterogeneous genetic aberrations found in transformed CLLs suggest that a genome-wide genetic instability is initiated during the transformation resulting in multiple genetic lesions.
A recently identified form of genetic instability, termed aberrant somatic hypermutation (ASHM), has been reported in different types of non-Hodgkin's lymphomas (NHLs), including a subset of DLBLs. [5] [6] [7] [8] [9] Aberrant somatic hypermutation is considered as a malfunction of somatic hypermutation (SHM), which is a physiological process in the immunoglobulin (Ig) variable genes of germinal center (GC) B-cells promoting affinity maturation. 10 Aberrant somatic hypermutation induces genomewide genetic instability by affecting multiple loci outside the Ig genes, including c-MYC, RhoH, Pax-5 and Pim-1 protooncogenes. 5 Activation-induced cytidine deaminase (AID) expression is associated with the B-cell differentiation taking place in the GCs, 11 and is required for SHM and class switch recombination of Ig genes in B-cells. 12 Several lines of evidences suggest that AID is highly mutagenic and its inadequate activity may lead to ASHM, and thus may contribute to the development of B-cell malignancies. 5, 8, 13, 14 To explore the role of ASHM and AID mRNA expression in the development of Richter's and PLT, we analyzed the mutational status of c-MYC, RhoH and Pax-5 genes, and the mRNA expression of AID in cases of CLL without and with Richter's and PLT. Our results indicate that ASHM and high mRNA expression of AID do not seem to have a role in the development of CLL, but they are associated with the development of Richter's and PLT.
Materials and methods

Pathological samples
Peripheral blood (PB) or lymph node samples of 29 patients with CLL were included in the study. Eight cases of CLL (cases [1] [2] [3] [4] [5] [6] [7] [8] showed no transformation during the clinical course of the disease, 13 cases (cases 9-21) developed RT and eight cases (cases [22] [23] [24] [25] [26] [27] [28] [29] showed PLT. In seven cases of RT (cases 9-15), both CLL and DLBL samples were available for analysis. In these cases, the CLL and the corresponding DLBL samples showed identical IgH gene rearrangements, indicating the common clonal origin of the tumor samples. All lymphoma samples were classified according to the World Health Organization (WHO) classification of tumors of lymphoid tissues. 3 The ratio of malignant cells in pathological specimens was more than 90%. The clinical data of patients, including stage, lymphocyte counts and platelet and hemoglobin levels are summarized in Table 1 .
Quantitative real-time polymerase chain reaction analysis of activation-induced cytidine deaminase mRNA expression
In total, 12 samples with CLL (cases 1-12), 13 samples with RT (cases 9-21) and eight samples with PLT (cases 22-29) were analyzed for AID mRNA expression. In four cases (cases 9-12), both CLL and RT samples were available for analysis. Mononuclear cells from the PB of eight healthy volunteers and GC B-cells from two reactive human lymph nodes were used as controls. Germinal centers were microdissected from the reactive lymph nodes, using Leica laser microdissection system (Leica Microsystems, Wetzlar, Germany), according to the manufacturer's instructions. Total RNAs were extracted using Trizol reagent (Invitrogen, Carlsbad, CA, USA), as recommended by the manufacturer. RNAs (2.5 mg) were reverse transcribed to cDNA using High Capacity cDNA Archive Kit (Applied Biosystems, Foster City, CA, USA). The quantitative real-time polymerase chain reaction (RT-PCR) assay was performed with ABI Prism s 7000 Sequence Detection System (Applied Biosystems, Weiterstadt, Germany). For amplification of the AID mRNA, a TaqMan s based Assays-on-Demandt Gene Expression product (Applied Biosystems) was used. The primers specific for AID amplify the wild type and all splice variants of AID. In order to normalize the AID values, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was amplified using a pre-developed TaqMan s Control Reagent (Applied Biosystems). All samples were run in triplicate, in a 20 ml reaction volume that contained 100 ng of cDNA. Sequence Detection Software version 1.0 (Applied Biosystems) was used to analyze the data after amplification. Results were obtained as threshold cycle (C t ) values. C t represents the cycle number at which fluorescence passes a fixed threshold. 
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The values were calculated as the mean values of three independent measurements, and the expression levels of AID mRNA were defined as a ratio of AID to GAPDH expression.
Statistical analysis
The values of AID mRNA expression were analyzed by Student's two-tailed t-test with unequal variances assumed. Differences in the expression levels were defined to be statistically significant for P-values less than 0.05. Figure 1 as relative expression values. As expected, the expression levels of AID mRNA were high in GCs and low in the PB of healthy volunteers. However, seemingly, there may be a difference between the AID mRNA expression levels of PBs of healthy volunteers and CLLs (Figure 1) , the results of the Student's two-tailed t-test showed that this difference is not significant (P ¼ 0.05709). There was no difference in the expression levels between the cases of CLL with and without transformation (P ¼ 0.38524). The AID mRNA expression levels were significantly higher in the cases of RT (P ¼ 0.00063) and PLT (P ¼ 0.04723) compared to the expression levels of the cases of CLL. In the four cases (cases 9-12) where both CLL and RT samples were available for analysis, the levels of AID mRNA expression in RT were 5.5-to 976-fold higher than in CLL.
Sequence analysis of c-MYC, Pax-5 and RhoH genes
The distribution and type of mutations found in c-MYC, Pax-5 and RhoH genes are reported in Table 2 and Figure 1 , and their general features are summarized in Table 3 . The sequence variants of the c-MYC gene reside in the region downstream of the major P1/P2 promoter (c-MYC exon 1) or/and the region downstream of the minor P3 promoter (c-MYC exon 2). The mutations in the RhoH gene were distributed within noncoding sequences, including the 5 0 region of intron 1, and the mutations in the PAX-5 gene reside in the 3 0 region (short part) of exon 1B and intron 1. The 15 CLLs carried a total of four mutations; three mutations were found in the nontransforming (cases 3, 4 and 6) and one mutation in the transforming (case 14) cases. The 13 RTs carried 32 and the eight PLTs carried 16 mutations. All but one mutations were single base-pair substitutions and one was an insertion. Of the 51 single base-pair substitutions observed, 23 were transitions and 28 were transversions. The transition-totransversion ratio was 1.0 for CLLs, 0.6 for RTs and 1.5 for PLTs. The nucleotide exchange pattern showed a G þ C/A þ T ratio of 1.0 in CLLs, 1.54 in RTs and 2.0 in PLTs. The involvement of the RGYW motif occurred in 25% of CLLs, 38% of RTs and 19% of PLTs. The mean mutation frequency of transformed cases ranged from 0.04/100 to 0.11/100 bp for the four analyzed gene regions. In the CLLs, only the c-MYC gene, but in the RTs and PLTs all the three genes carried mutations. The number of mutated genes in CLLs ranged from 0 to 1, and in RTs and PLTs it ranged from 1 to 3.
In seven cases (cases 9-15), both CLL and RT samples were available for mutational analysis. In this group, only one CLL sample (case 14) carried a single base-pair mutation (4552 A4G), which was shared by the corresponding RT. This RT sample also acquired an additional mutation. All the other RTs carried 1-4 mutations. The mutations showed no intraclonal divergence.
Sequence analysis of IgV H genes
The mutational frequency of IgV H genes is reported in Table 1 . Based on the number of nucleotide differences from germline genes, cases are divided into two groups. Samples in which fewer than 2% of base pairs differed from those of the consensus sequence for V H gene are considered unmutated (cases 1, 3, 7, 9-21 and 24-28), whereas cases in which more than 2% of base pairs differed from consensus V H gene sequence fall into the mutated group (cases 2, 4, 5 and 8). 16 In the control CLL group, which did not transform to higher-grade lymphoma, four cases were mutated and three cases were unmutated. All of the 
Discussion
To determine the role of AID and ASHM in the development of RT and PLT of CLL, quantitative RT-PCR analysis of AID and the mutational status of c-MYC, RhoH and Pax-5 genes were analyzed in cases of CLL without transformation and with RT and PLT. Our results provide evidences that high expression of AID mRNA and ASHM are associated with the development of RT and PLT in CLL patients. In line with previous reports, 17, 18 all CLLs analyzed in this study expressed AID mRNA at various levels but the expression levels remained well below that of normal GC B-cells. Chronic lymphocytic leukemia cases that showed no transformation and cases that eventually transformed to higher-grade lymphoma expressed AID at similar levels. Interestingly, mRNA expression was significantly higher in both RT and PLT compared to the AID expression of CLLs, and they reached the level of expression of 'de novo' DLBLs (data not shown). The transformation-related elevation of AID expression was also demonstrated by the four cases where clonally related CLL and transformed DLBL samples were available for analysis. In these cases, the AID expression of CLLs increased 5.5-to 976-fold in transformed cells. However, AID expression is restricted to healthy GC B-cells 11 and constitutive expression of AID characterize lymphomas of GC origin, 19, 20 our results provide evidences that AID expression may increase significantly during the clonal history and evolution of a neoplastic B-cell clone, and may contribute to higher-grade transformation of CLLs.
The increased AID expression in transformed CLLs suggests alternative pathways for the development of RT and PLT.
Albesiano et al. 17 provided evidences by a limiting dilution assay that AID expression is heterogeneous in the tumor cell population of CLL, and only a small fraction of cells express AID. Based on this observation, it is possible that high expression of AID detected in transformed cases is the result of intensive clonal selection of AID expressing cells. Alternatively, it is also possible that pathways that initiate AID expression are activated during the transformation of B-CLL. This concept is supported by the findings that CLL cells may increase AID expression through CD40 and IL-4 signaling, 17, 21 and that CLL cells have remarkably high levels of AID expression in tissue microenvironment. 22 Since higher-grade transformation of B-CLL mostly occurs in lymph nodes, it is possible that tissue microenvironment provides specific signals for AID expression, and disregulated AID activity leads to mutations of different oncogenes to drive clonal evolution of CLL cells.
The elevated AID expression of transformed CLLs found in this study raises the question whether AID generally plays a role in the process of tumor progression and transformation of lowgrade lymphomas. The limited number of cases studied provided conflicting results. In three of seven follicular lymphomas (FL), clinical progression and higher-grade transformation was associated with elevated AID expression, 19 but transformation of FL to DLBL showed no discernable increase in AID expression upon transformation. 23 In agreement with our findings, these reports suggest that in some cases of FLs, AID might have a role in tumor progression. Although, the absence of AID elevation in transformed FLs does not necessarily mean that AID has no role in the transformation, since FLs generally have a higher basal level of AID expression than CLLs, and this level of AID expression might be enough to generate genetic instability and tumor progression.
20 Table 3 Features of c-MYC, Pax-5 and RhoH mutations in cases of chronic lymphocytic leukemia without transformation, and cases with Richter's and prolymphocytic transformation
Locus
Mutations/100 bp (range) No. CLL, chronic lymphocytic leukemia; PLT, prolymphocytic transformation; RT, Richter's transformation; No. of mutation frequencies were calculated on the entire region analyzed and on mutated cases only, taking into account both alleles; RGYW shows the number of mutations embedded in this
Single bp substitutions
Frequent ASHM has been described in a subset of DLBLs, [5] [6] [7] [8] [9] but it is mostly absent in indolent lymphomas, including CLL. 5, 9 To determine whether RT and PLT of B-CLLs are associated with activation of ASHM, we have analyzed the mutations of c-MYC, RhoH and Pax-5 genes in CLLs without and with RT and PLT. In accordance with previous reports, 5, 9 we found low frequency of mutations in c-MYC, RhoH and Pax-5 genes in B-CLLs, supporting the findings that ASHM does not play a role in the development of CLL, not even in those CLL cases that later transform to a more aggressive disease. Similarly to 'de novo' DLBLs, the c-MYC, RhoH and Pax-5 genes were highly mutated in both RTs and PLTs. The mutation frequency, the nucleotide substitutions with a prevalence of G þ C over A þ T and involvement of the RGYW motifs by the mutations were comparable to that reported as ASHM. [5] [6] [7] [8] [9] The mutated c-MYC, RhoH and Pax-5 genes in transformed CLL cases suggest that ASHM is activated during the process of transformation, but we cannot exclude the possibility that ASHM is generated after the transformation, in the transformed high-grade lymphoma cells. In those seven cases where CLL and clonally related RT samples were available for mutation analysis, only one CLL showed a single mutation, which was also detected in the transformed stage of the disease. Besides this mutation, the transformed RT developed an additional mutation suggesting that ASHM span the process of transformation. Furthermore, the absence of the ongoing feature of mutations in the transformed CLL cases suggests that the window for ASHM was open for a short period, probably at the time of the transformation, and was closed at the transformed stage of the disease.
In harmony with our prior report, 24 the transforming CLLs, the transformed RTs and PLTs showed unmutated IgV H gene status and the somatic mutation mechanism of the IgV H gene was not activated during the higher-grade transformation of CLLs. These findings suggest that the phisiological process of SHM and ASHM are not necessarily linked together, and ASHM may occur independently of Ig gene mutations.
However, this study suggests a correlation between AID expression and ASHM in higher-grade transformation of CLL, it is difficult to define which event initiates the transformation, because the time of their occurrence in relation to the transformation is not readily determinable. The initiative role of AID expression in the molecular events of lymphoma development has been demonstrated by experimental models of transgenic mice where constitutive expression of AID initiated massive point mutations in different oncogenes. 13, 25 Furthermore, the mutations of Ig genes in the preswitch region can be induced by modulating AID expression in CLL B-cells. 26 In contrast to these findings, we cannot exclude the possibility that a subset of genetically altered CLL cells acquire ability to express AID. This later theory is supported by the in vitro stimulation studies, where only a subpopulation of CLL cells is inducible to express AID. 17 Nevertheless, this study provides further evidences that AID expression and ASHM may occur together and suggests that they might have a role in higher-grade transformation of CLL.
